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Abstract The cap is a natural modification present at the 50 ends of eukaryotic
messenger RNA (mRNA), which because of its unique structural features, mediates
essential biological functions during the process of gene expression. The core
structural feature of the mRNA cap is an N7-methylguanosine moiety linked by a
50–50 triphosphate chain to the first transcribed nucleotide. Interestingly, other RNA
50 end modifications structurally and functionally resembling the m7G cap have
been discovered in different RNA types and in different organisms. All these
structures contain the ‘inverted’ 50–50 oligophosphate bridge, which is necessary for
interaction with specific proteins and also serves as a cleavage site for phospho-
hydrolases regulating RNA turnover. Therefore, cap analogs containing
oligophosphate chain modifications or carrying spectroscopic labels attached to
phosphate moieties serve as attractive molecular tools for studies on RNA meta-
bolism and modification of natural RNA properties. Here, we review chemical,
enzymatic, and chemoenzymatic approaches that enable preparation of modified cap
structures and RNAs carrying such structures, with emphasis on phosphate-modified
mRNA cap analogs and their potential applications.
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1 RNA Cap Structures and Their Functions
1.1 7-Methylguanosine mRNA Cap
The existence of methylated guanine joined by a 50–50-triphosphate linker to the first
transcribed nucleotide of eukaryotic and viral messenger RNA (mRNA) was first
reported in the mid-1970s independently by Wei [1] and Furuichi [2] (Fig. 1). Since
then, cap has emerged as a master regulator of several processes contributing to
gene expression in eukaryotes. Besides its two main cytoplasmic roles, i.e.,
protection of the mRNA 50 end from premature degradation by exonucleases and
participation in the initiation of protein synthesis (translation), cap is also required
for proper splicing of precursor mRNA (pre-mRNA) in the nucleus, engaged in
cleavage and polyadenylation of pre-mRNA, and mRNA export (Fig. 2) [3–5].
Fig. 1 Structures of different RNA 50 ends: a uncapped (50-triphosphate) RNA; b monomethylguanosine
(m7G) mRNA cap; c trimethylguanosine (m3G) cap and c-O-methyl cap found in snRNAs; d examples of
‘cap-like’ structures found on bacterial RNAs
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Therefore, it is not surprising that cap formation is the first co-transcriptional event
of a nascent RNA synthesized by RNA polymerase II (RNAP II), which occurs after
synthesis of 20–40 nucleotide long transcripts [6]. Many viruses that infect
eukaryotes have evolved mechanisms to either synthesize their own cap structures
or salvage cap moieties from host mRNA through so-called cap snatching to
maximize the chances for their own mRNA survival and expression [7]. The
protective function of mRNA cap relies on the fact that cytoplasmic 50–30
exoribonucleases, such as Xrn1, do not recognize capped mRNAs as substrates.
Therefore, mRNA degradation initiated from the 50 end must be preceded by cap
removal by specialized decapping enzymes. Another class of decapping enzymes is
involved in degradation of free cap structures generated after 30–50 mRNA decay
(Fig. 2).
Synthetic cap analogs are useful research tools that facilitate investigation of cap-
related processes both at a molecular level and in biochemical and biological
experiments, which may eventually lead even to development of novel therapeutic
approaches [8]. In this paper, we review approaches employed to develop cap-based
molecular tools that could benefit biological studies, with the focus on phosphate-
labeled and phosphate-modified cap analogs of m7G cap and other structurally
related RNA cap structures.
Fig. 2 An overview on RNA cap functions in gene expression and main proteins involved in cap
recognition and metabolism
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1.2 m7G Cap 0, 1, 2 and Other Cap Structures
Although the term cap usually refers to the m7G moiety linked to the 50 end of a
transcript, different versionsof them7Gcaphavebeen recognizedalongwithother types
of cap structures found on different RNA types and in various organisms. Depending on
themethylation pattern of the first few 50-nucleotides in anm7G-capped RNAbody, cap
variants referred to as cap 0, cap 1, cap 2, and so on, can be distinguished (Fig. 1b). In
addition, other types of methylated cap structures have been identified in eukaryotes,
trimethylguanosine andc-methyl cap being the prime examples (Fig. 1c). Finally, itwas
recently discovered that prokaryotes also synthesize conjugates of RNA with small
molecules that structurally resemble eukaryotic 50 caps (Fig. 1d).
Cap 0 is m7G cap without additional methylations in the RNA body. However, cap 0
can undergo further methylations at the 20-O position within the ribose of the first or
within the first and second nucleotide to produce cap 1 or cap 2, respectively (Fig. 1b)
[9]. Generally, cap 0 structures are more common in lower eukaryotes, whereas cap 1
and cap 2 structures are found in higher organisms, including mammals [9]. Additional
methylations at the first and second nucleobase of mRNAs can also take place in cap 1
and 2. For a long time, it was unclear why the 50 end of mRNAs would undergo such
extensive methylation. Recent studies have revealed that 20-O methylation of cellular
RNA plays a central role in discrimination of self from non-self RNA, e.g., distinction
of viral from host RNA [10, 11], while reversible interconversion of N6, 20-O-
dimethyladenosine and 20-O-methyladenosine in the cap controls mRNA stability [12].
Not only nucleotides downstream from m7G undergo methylation. In some small
nuclear RNAs (snRNAs) involved in splicing of pre-mRNA, the m7G moiety
undergoes hypermethylation, i.e., addition of two methyl groups at the N2 position
(Fig. 1c). This structure, called a trimethylguanosine cap (TMG cap or m3G), is
characteristic of a portion of snRNAs transcribed by RNAP II, namely U1, U2, U4,
and U5 snRNAs, and small nucleolar RNAs (snoRNAs) engaged in post-
transcriptional modification of precursor ribosomal RNAs (pre-rRNAs) [13]. These
snRNAs are hypermethylated by trimethylguanosine synthase 1 (TGS1) after being
exported to the cytoplasm in association with Sm proteins (Fig. 4) [13, 14]. The
presence of a TMG cap allows binding to the transport protein snurportin 1 (SNP1)
and the import of fully matured snRNAs back to the nucleus, where they participate
in pre-mRNA splicing [14]. Moreover, the TMG cap has been found at the 50 end of
a certain pool of mRNAs in nematodes (e.g., Caenorhabditis elegans) [15], and
most recently at the 50 end of mRNAs encoding selenoproteins in mammals [16].
Interestingly, other snRNAs, such U6 and 7SK, which are synthesized by RNA
polymerase III (RNAP III), possess at their 50 end another modification, a methyl
group added directly to triphosphate bridge to generate a c-methyl phosphate cap
(Figs. 1c, 4) [17]. However, the presence of a methyl group linked directly to a
triphosphate bridge is not a general feature of RNAP III-transcribed RNAs (e.g.,
tRNAs), as usually the triphosphorylated 50 ends of nascent transcripts are trimmed
by nucleases to RNAs without cap-like structures upon maturation.
Although it has been hypothesized for a long time that the presence of the 50 cap
is one if the key structural features distinguishing eukaryotic from prokaryotic
RNAs, recent mass spectrometry-aided studies on bacterial transcriptomes revealed
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that in prokaryotes, the 50 ends of some portion of RNA are modified by moieties,
which could be considered as cap-like structures. These include a nicotinamide
adenine dinucleotide (NAD?) [18], 30-dephospho-coenzyme A (dpCoA) (Fig. 1d)
[18], and other moieties attached to the 50 end of RNA by an oligophosphate bridge.
The structure, biosynthesis, function, and degradation of these so-called bacterial
caps have currently come under intense investigation [19–22].
1.3 Recognition of Cap Structures by Proteins
The complex network of biological processes regulating mRNA expression and
turnover is in large extent orchestrated by numerous cap-binding proteins that
recognize the 7-methylguanosine triphosphate moiety as a hallmark of the mRNA 50
end. Similarly, the localization, transport, and function of immature and mature sn/
snoRNA largely rely on binding by proteins that recognize their m7G and m3G caps,
respectively. Although these proteins are usually unrelated in terms of function and
sequence, they often share similarities in cap recognition modes. Based on the crystal
structures and thermodynamic data of numerous cap-binding proteins and enzymes in
complex with m7G or m3G derivatives, the selectivity of cap recognition could be
attributed to its two distinctive features: a positively charged nucleobase and a
negatively charged 50–50-triphosphate bridge. Interaction patterns that are common in
all proteins include (i) cation-p stacking interactions involving 7-methylguanine or
2,2,7-trimethylguanine and (ii) hydrogen bonds between the oligophosphate bridge
and positively charged side chains of basic amino acids assisted by electrostatic
attraction of unlike charges (Fig. 3). In themajority of complexes, 7-methylguanine is
stacked with the indole moiety of tryptophan residue (eIF4E, SPN1, DcpS, cNIIIB,
TGS1) and often forms sandwich complexes employing another side chain of an
aromatic amino acid such as Trp, Tyr, Phe (eIF4E, cNIIIB, CBC, VP39) or even the
base of the second nucleoside (SPN1) [23–30]. Interestingly, in most of these
structures, the N7-methyl group is not in direct contact with protein, yet its removal
reduces the affinity ofm7GTP to eIF4E by several orders ofmagnitude, suggesting that
the specificity of m7G recognition is mainly determined by the presence of a positive
chargewithin the nucleobase [24].Another structural feature influencing the affinity to
cap-binding proteins is the oligophosphate chain. Usually, at least two arginine or
lysine residues are engaged in hydrogen bonds with the triphosphate bridge, but the
geometry of those interactions differs from one protein to another.
2 Chemically and Enzymatically Labeled RNA Caps
2.1 Utility of Labeled Capped RNAs and Cap Analogs
Nowadays, capped RNAs can be easily obtained on a small scale by standard
molecular biology techniques and used for the purpose of RNA-driven gene
expression of proteins of interest in living cells or cell lysates [31]. Variously
modified cap analogs are used as small molecule binding and activity probes for
cap-binding proteins and cap-processing enzymes. Finally, capped RNAs and small
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molecule cap analogs are utilized to study RNA turnover in various biological
systems. For biochemical studies, capped RNAs, cap analogs, and their degradation
products isolated from biological mixtures are often resolved by thin layer
chromatography (small nucleotides) or electrophoresis (oligos and nucleic acids)
and visualized by different methods. Because of low concentrations of RNA and cap
Fig. 3 Recognition of mRNA cap structure by different proteins relies on cation-p stacking of
7-methylguanosine and electrostatic interactions with an oligophosphate chain. a Murine translation
initiation factor 4E (meIF4E) in complex with m7GpppG (pdb entry 1L8B) [24]; b cap-binding domain of
human snurportin 1 (SPN1) in complex with m3GpppG (pdb entry 1XK5) [25]; c human decapping
scavenger mutant (hDcpS H277N) in complex with substrate, m7GpppG (pdb entry 1ST0) [26];
d Saccharomyces cerevisiae decapping protein 2 (Dcp2) in complex with cap analog, m7GpSpppSm
7G
(pdb entry 5KQ4) [27]; e Drosophila melanogaster cytosolic nucleotidase IIIB (Ds cNIIIB) in complex
with product, m7G, and MgF3
- as a transition state phosphate mimic (pdb entry 4NV0) [28]; f human
nuclear cap-binding complex subunit (CBC20) in complex with m7GpppG (pdb entry 1N52) [29];
g human trimethylguanosine cap synthase 1 (hTGS1) in complex with substrate analog, m7GTP and
product S-adenosylhomocysteine (SAH) (pdb entry 3GDH) [30]; h Vaccinia virus 20-O methylase VP39
in complex with a capped RNA fragment and SAH (pdb entry 1AV6) [23]
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metabolites in typical samples, standard visualization techniques, such as UV
shadowing, do not provide sufficient sensitivity nor selectivity in detection, which
impairs analysis of complex nucleotide and nucleic acid mixtures. Although
fluorescent staining reagents are used to increase sensitivity of nucleic acid
detection, they are not useful for detection of short oligos and small nucleotides.
Therefore, methods for generation of specifically labeled RNAs carrying radioac-
tive, fluorescent, and other spectroscopic labels are constantly being developed to
provide highly sensitive and selective tools for detection of the molecule of interest
in a complex mixture or to selectively monitor a particular enzymatic reaction or
binding event. In the following sections, we will review enzymatic, chemoenzy-
matic, and chemical approaches enabling RNA cap labeling, with the main
emphasis on modifications of the triphosphate chain and their utility in studying
RNA-related processes. We start from the well-established enzymatic approaches,
which rely on the use of radioactively labeled Nucleoside triphosphates (NTPs), and
RNA-processing enzymes. We then discuss chemical approaches to the synthesis of
phosphate-modified or -labeled cap analogs, followed by examples of their utility as
molecular probes for studying cap-related processes and reagents for modification
of RNA oligonucleotides and long transcripts.
2.2 Cap Biosynthesis
In vivo m7G capping of a nascent transcript occurs in three sequential steps
catalyzed by specific enzymes, namely, RNA triphosphatase (TPase), RNA
guanylyltransferase (GTase), and guanine-N7 methyltransferase (guanine-N7
MTase) (Fig. 4) [32]. First, RNA TPase removes the 50 c-phosphate from ppp-
RNA to generate RNA 50-diphosphate. Subsequently, RNA GTase transfers guanine
monophosphate (GMP) from GTP to the b-phosphate of RNA to form Gppp-RNA
in a reversible two-step ping-pong reaction with lysine-GMP intermediate [33]. The
last step of m7G cap 0 formation is transfer of a methyl group from S-adenosyl-L-
methionine (SAM) to the N7 position of the terminal guanine catalyzed by guanine
N7 MTase [33]. Further optional methylations leading to cap 1 and cap 2 are
performed by other enzymes called 20-O methyltransferases (20-O MTases) (Fig. 4).
Interestingly, formation of cap 0 and cap 1 takes place in the nucleus, while
methylation of cap 1 to produce cap 2 is a cytoplasmic event [34]. The m7G-capping
mechanism dependent on three distinct enzymatic activities is shared from fungi to
higher mammals and utilized by some eukaryote-associated viruses. One such virus
is vaccinia, which encodes its own heterodimeric 127 kDa capping enzyme
(vaccinia capping enzyme, VCE) that combines all three capping activities
necessary for cap 0 biosynthesis. The enzyme was first characterized in 1980
[35], and since then has been extensively studied, and is now a commercially
available molecular biology tool widely used to produce capped transcripts,
including radioactively labeled ones.
The biosynthesis of other eukaryotic cap structures usually relies on post-
transcriptional RNA modification. TMG-capped RNA (m3GpppRNA) is produced
by methylation of m7GpppRNA with TGS1 methyltransferase, which acts in vivo
on immature U1, U2, U4, and U5 snRNAs, whereas the c-methyl cap
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(CH3pppRNA) is generated by methylation of U6 5
0-triphosphate snRNA with c-
MTase (Fig. 4). Similarly, it was first proposed that biosynthesis of NAD-capped
RNAs in bacteria occurs through the post-synthetic addition of a nicotinamide
nucleotide to the 50 end of RNA [21, 32], but recent studies indicate that this kind of
‘capping’ is rather carried out by bacterial RNA polymerases, which use NAD as a
transcription initiator [34].
2.3 Possible Sites for Cap Modification
From the bioorganic chemist’s point of view, the structural studies provide insights
not only into the recognition mode of natural cap structures but also hints at the
design of chemically modified cap analog-based molecular tools tailored for specific
applications. In general, modifications of the cap should serve at least one of three
purposes: (i) to perturb or even completely destroy biological activity (e.g.,
inhibition of degradation by decapping enzymes); (ii) to increase affinity to
particular cap-binding proteins, thereby augmenting associated biological activity;
(iii) to confer a new property to the cap structure without any interference with its
biological activity (biorthogonal modifications).
Sites for biorthogonal modifications of the cap could be envisaged based on their
crystal structure in complex with a targeted cap-binding protein (Fig. 3). For
example, in the case of eIF4E complex, both m7G hydroxyl groups and the second
nucleoside are exposed to the solvent, and, in fact, these groups were successfully
functionalized with various substituents without significant decrease in affinity
constant. Consequently, the translational activity of mRNAs carrying such cap
structures was at least retained [36–39]. In contrast, ribose of m7G in complex with
DcpS is engaged in numerous contacts and any modification within 20-O and 30-
O positions results in a considerable decrease of the rate of hydrolysis catalyzed by
DcpS [40, 41]. Importantly, the triphosphate bridge appears to be an attractive site
Fig. 4 Enzymatic pathways to generate various eukaryotic cap structures on RNA 50 ends
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for modification, especially in the context of conferring resistance to decapping
enzymes. Because the decapping enzymes involved in 50–30 and 30–50 decay cleave
the triphosphate chain at different positions (a,b- and b,c-, respectively) and employ
different mechanisms to perform catalysis, it is possible to develop modifications
that affect decapping at only one selected position or at both positions.
2.4 32P Labeling of RNA Caps by Enzymatic Approaches
Capped RNAs and cap analogs radiolabeled with 32P were one of the first tools that
enabled biochemical studies of the structural details, functions, and metabolism of
mRNA and snRNA caps. One of the most important applications of such tools is to
investigate the biochemical activities of cap-specific enzymes involved in RNA
turnover. Synthesis of 32P-labeled capped mRNA is usually achieved by transcrip-
tion of a DNA template in vitro, followed by post-transcriptional enzymatic capping
using radiolabeled NTP in at least one of the synthetic steps. Knowing the
mechanistic details of phosphate transfer reactions taking place during transcription
and capping reactions allows the design of methods to produce transcripts that are
site-specifically radiolabeled within or in the vicinity of the cap attached to either a
uniformly radiolabeled or unlabeled RNA body.
2.4.1 Incorporation of 32P into RNA Caps
Usually, RNAs used for biochemical studies are generated in transcription reactions,
in which DNA-dependent RNA polymerase uses four unlabeled (‘cold’) NTPs to
transcribe the DNA sequence encoding a specific promoter region recognized by the
polymerase and sequence the region of interest into RNA (Fig. 5). To obtain RNAs
radiolabeled at the a position of the cap’s triphosphate bridge (m7Gppp*RNA or
CH3ppp*RNA, where p* denotes
32P-labeled phosphate), a ‘hot’, a-phosphate-
labeled version of the first transcribed NTP ([a-32P]NTP) is added to the
transcription reaction. This initially yields transcripts radiolabeled at the a position
of the 50-triphosphate moiety (ppp*RNA), which can be subsequently subjected to
capping by VCE or c-MTase under standard conditions to yield the desired product
(Fig. 5). To obtain capped RNAs radiolabeled within the first phosphodiester bond
(e.g., m7GpppNp*RNA) the [a-32P]NTP version of the second transcribed
nucleotide is added to the transcription reaction, followed by enzymatic capping
(Fig. 5). Finally, 32P can be introduced at the c position of a cap’s triphosphate
chain (to produce m7Gp*ppRNA) by adding [a-32P]GTP into the VCE-mediated
capping reaction performed on ‘cold’ RNA (Fig. 5). Notably, this approach is
different from the two previous ones as it leaves the rest of the RNA body
completely unlabeled. It is also possible to obtain RNA selectively radiolabeled at
the b-phosphate of the cap by adding an appropriate [b-32P] NTP to the transcription
reaction [42]. However, to our knowledge, this approach is rarely used, likely owing
to a lack of commercial availability of [b-32P] NTPs.
32P labeling can be performed in vitro to create RNA of a pre-determined
sequence, but can also be applied to the synthesis of total RNA in cell extracts
followed by biochemical analysis. The latter approach has been employed a number
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of times in different organisms and on various RNA types to analyze the RNA 50
end heterogeneity, with the focus on both the distal cap modification and the
nucleosides at the positions ?1 and ?2. To this end, total RNA is transcribed in cell
extract in the presence of one or more ‘hot’ NTPs. The transcripts are resolved by
electrophoresis, fractions of interest excised from the gel, and subjected to
degradation by 30–50 nuclease such as RNase P1 or a cocktail of ribonucleases,
optionally followed by alkaline phosphatase, which releases nucleosides and
inorganic phosphate from the RNA body but leaves undigested RNA 50 ends of
Xppp(Np)n (where n = 1–3). Released radioactive products can be analyzed using
2D TLC, usually on cellulose plates, or high-performance liquid chromatography
(HPLC) on reversed-phase or ion exchange columns. Alternatively, RNA cleavage
can be performed with a more specific endonuclease. For instance, RNase T1
cleaves RNA after 30-guanylic residues leaving a 30-phosphate and a 50-OH in the
products. This RNase is particularly useful for the analysis of transcripts initiated
with G and labeled within the first transcribed phosphodiester bond (XpppGp*N-
RNA), because it cleaves them to release radiolabeled cap structures of XpppGp*
type (along with other RNA fragments). The identity of the cap structures can be
confirmed by isolation and further digestion by a pyrophosphatase with broad
specificity, such as tobacco acid pyrophosphatase (TAP), which cleaves both
triphosphate bonds. This approach has been used to identify 50 ends of eukaryotic
and viral mRNAs, snRNAs, and snoRNAs [42–45], as well as to verify the
Fig. 5 Generation of differently 32P-labeled RNAs using in vitro transcription followed by enzymatic
capping. Depending on the template sequence and ‘hot’ NTP used in the transcription reaction, RNA can
be labeled at the a position within the cap triphosphate bridge (1) or at the first phosphodiester bond of
transcribed RNA (2). Alternatively, the c-phosphate of the cap structure can be specifically labeled if
‘hot’ GTP is used in VCE-catalyzed capping (3)
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efficiency of incorporation and orientation of synthetic dinucleotide cap structures
introduced into RNA co-transcriptionally [36, 46, 47].
2.4.2 32P-Labeled RNAs and Cap Analogs in the Study of RNA Turnover
Another important use of radiolabeled capped RNAs is for gaining new insights into
mRNA and cap turnover. Cap turnover starts when a transcript is subjected to
cellular RNA degradation machinery. There are two main mRNA degradation
pathways 50–30 and 30–50, both initiated by poly(A) tail shortening [48]. Although
decapping is not the first event in the 50–30 mRNA degradation pathway, as it is
preceded by deadenylation, it is considered as the first highly irreversible step. In
eukaryotes, Dcp1/2 serves as the main decapping enzyme [49]. Dcp2 is a catalytic
subunit belonging to the Nudix family of hydrolases [50, 51] whereas Dcp1 is a
regulatory subunit, which can interact with additional decapping enhancers such as
Edc1, 2, and 3, or PNRC2 [52].
Biochemical analysis using m7Gp*pp- and m3Gp*pp-capped mRNAs and
snRNAs revealed that human and yeast Dcp2 hydrolyze the cap exclusively
between a and b phosphates to yield [a-32P]m7GDP or [a-32P]m3GDP and RNA 50-
monophosphate [50, 51, 53] which can undergo further degradation by 50-
exonucleases (Fig. 6). Dcp2 requires the RNA body for activity as it does not
hydrolyze m7Gp*ppG in vitro [53]. Recently, it has been found that, at least in vitro,
several other enzymes, such as Nudt16, Dxo1, and Rai1, can catalyze RNA
decapping at the a-b position [54–56], but their exact roles in RNA degradation
in vivo are yet to be established.
In contrast, the second main enzyme engaged in cap turnover—DcpS, which is
responsible for depletion of products of 30–50 RNA decay—prefers cap dinu-
cleotides as substrates [57]. m7Gp*ppN dinucleotides and short m7Gp*pp-RNAs are
hydrolyzed by recombinant DcpS between b and c phosphates to yield m7Gp* and a
downstream nucleoside or RNA 50-diphosphate [57–59].
Both decapping pathways produce either m7GMP or m7GDP mononucleotides as
reaction products. For a long time, it was hypothesized that cells must have
developed mechanisms that protect them from accumulation of m7G nucleotides,
which either could inhibit cap-dependent proteins or, after conversion into m7GTP,
be erroneously salvaged by RNA polymerases. A study on degradation of
enzymatically generated m7Gp*ppG-RNA and m7Gp*p in mammalian cell extracts
using TLC and autoradiography suggested that an additional function of DcpS in
mRNA decay is to cleave m7GDP to m7GMP [60]. However, it was later shown that
m7GDP, in contrast to m7GpppG and m7GTP, is not a substrate for DcpS, and at
least in vitro acts as a DcpS inhibitor [61]. A new study performed in yeast and
mammalian cell extracts on m7Gp*ppG, m7Gp*p, and m7Gp* revealed that m7GDP
metabolism may proceed through its phosphorylation to m7GTP carried out by
nucleoside diphosphate kinase (NDPK) and subsequent degradation by DcpS to
m7GMP [62]. Interestingly, m7GMP is not the end product of cap metabolism in
yeast, as degradation of m7Gp*ppG led to only small amounts of m7Gp* and high
amounts of radioactive Pi and some unidentified metabolite X with TLC mobility
similar to Pi [62]. This study has also shown that in the absence of DcpS activity
Top Curr Chem (Z) (2017) 375:16 Page 11 of 29 16
123
(gene knockout), the Fhit enzyme can take part in m7Gp*ppG turnover by cleaving
it between a and b phosphates to release m7Gp*p [62]. Even less is known about
m7GMP metabolism, although a cytosolic nucleotidase III-like enzyme (cNIII) has
been described that utilizes m7GMP as a substrate (Fig. 6) [63].
32P-labeled capped RNA oligonucleotides were used to evaluate the suscepti-
bility of various synthetic cap structures modified in the triphosphate bridge
(discussed in more detail below) to Dcp2 [64, 65] and to screen potential inhibitors
of Dcp2-catalyzed decapping [66]. If short capped RNA oligonucleotides (up to 50
nt) were used as Dcp2 substrates, the electrophoretic resolution of capped and
decapped RNAs could be performed directly on sequencing gels.
2.4.3 Enzymatic Labeling Beyond Radioactive Phosphates
As described in the previous section, by taking advantage of enzymes engaged in
cap biosynthesis and turnover, it is possible to generate 32P-labeled versions of
variously capped RNAs, different cap structures, and cap metabolites, which
provide tools instrumental in numerous biological studies (Fig. 6). However,
labeling with 32P has some limitations such as the production of unpredicted
radioactive metabolites or incompatibility with continuous (on-line) enzymatic
activity monitoring, in vivo studies, and in cellulo visualization. Therefore, labeling
methods directed towards introduction of fluorescent labels or biological tags into
Fig. 6 Investigation of RNA degradation and cap turnover pathways using ‘hot’ c-phosphate-labeled
capped RNA. The main enzymes involved in these processes in vivo are marked in bold. Schematic
representation of a typical TLC analysis of cap turnover in the presence of different enzymes
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capped RNA are constantly being developed. Interestingly, some of those methods
rely on the same biochemical approaches as those developed for radioactive
labeling. For example, it has been recently reported that VCE apart from GTP
accepts certain GTP analogs as substrates, including those functionalized at the
ribose moiety [67–69]. Taking advantage of this, VCE has been independently used
to transfer a biotinylated [69] or anthraniloylated [68] GMP moiety to the 50 end of
RNA from a GTP analog appropriately functionalized at the ribose moiety. Notably,
the label structure is of great importance for success in this approach, since a similar
reaction using GTP carrying a manthraniloyl dye failed to produce capped
transcripts [68]. Another interesting chemo-enzymatic approach to enzymatic cap
labeling proposed by Rentmeister et al. takes advantage of methyltransferase
activity of trimethylguanosine synthase 2 from Giardia lamblia (GlaTgs2-Var1).
GlaTgs2-Var1 was first mutated (V34A) to accommodate bulkier, chemically
modified analogs of S-adenosyl-L-methionine (SAM) as co-substrates [70–72],
thereby allowing for transfer of various functional groups from synthetic SAM
analogs onto the N2 position of an m7G moiety within the cap. The introduced
functional groups were reactive in so-called click reactions such as cop-
per(I) (CuAAC) or strain promoted azide-alkyne cycloaddition (SPAAC), tetrazole
photoclick (PC), thiol-ene conjugation (TEC) and inverse electron-demand Diels–
Alder cycloaddition (IEDDA) and, as such, were used to label a dinucleotide 50 cap
analog m7GpppA with properly functionalized fluorescent dyes. Although such
modifications of N2 position are expected to disturb mRNA activity in translation,
they have great potential for applications related to labeling and quantification of
endogenous or exogenously delivered RNAs in vitro and in vivo. Recently, another
methyltransferase—Ecm1 from the microsporidian parasite Encephalitozoon cuni-
culi—was shown to transfer some bulky residues from SAM analogs to the N7 atom
of GpppG capped transcripts [72]. Such functionalized mRNAs were then delivered
into HeLa cells by transfection where they reacted with dibenzocyclooctyne
functionalized sulforhodamine B in a SPAAC reaction.
2.5 Chemical and Chemoenzymatic Approaches Towards Phosphate-
Modified Cap Analogs
2.5.1 Possible Sites for Chemical Modifications of the RNA Caps
The repertoire of available enzymatic methods to modify cap structures is restricted
by substrate specificity of particular enzymes. Much greater versatility of cap
analogs can be generated by means of chemical synthesis. The influence of chemical
modifications within the cap on its biological properties has been studied almost
since the very moment of cap discovery. To date, almost every position of m7G and
TMG cap structures has been chemically modified, and the influence of those
modifications on interaction with cap-binding proteins has been studied, often
followed by the determination of the biological consequences of such modifications
on RNA stability, transport, and translation. Interestingly, triphosphate chain
modifications were explored much later than modifications of the 7-methylguanine
or ribose moieties [36, 73–76], but turned out to have great potential to modulate the
Top Curr Chem (Z) (2017) 375:16 Page 13 of 29 16
123
interactions of the cap-structure with cap-binding proteins and its susceptibility to
different decapping enzymes.
In the next paragraphs, we describe the variety of phosphate modifications that
can be introduced into mRNA cap analogs by means of chemical synthesis followed
by their selected biochemical, biological and even medicinal applications, as small
molecules, as a part of RNA oligonucleotides, and as full-length transcripts.
2.5.2 Synthesis of RNA Caps: P-Imidazolides and MCl2-Mediated Coupling
The main challenge in chemical synthesis of cap analogs is the formation of the
pyrophosphate bonds from two different phosphate derivatives necessary to attain
an asymmetrically substituted oligophosphate bridge. The most commonly used
method relies on conversion of one of the phosphate substrates into P-imidazolide,
which could be then coupled with an appropriate nucleophile in a MCl2-mediated
reaction (where M stands for metal, usually Zn or Mg) [77, 78]. Such an approach
provides a relatively simple way to obtain a wide scope of chemically modified
oligophosphate mono- and diesters (Fig. 7), including phosphorothioates [79–81],
seleno- [82], borano- [83], and fluorophosphates [84], as well as phosphoramidates
[85], C-phosphonates [86], and bisphosphonates [87]. P-imidazolides were shown to
react readily with other inorganic nucleophiles such as fluorides [84] and sulfates
[88] to yield fluorophosphates and phosphosulfates, respectively.
An important limitation of this method lies in the synthesis of P-imidazolides,
which is very efficient for non-modified mono-, di-, and even triphosphates but fails
to produce a satisfactory yield of the desired product from compounds modified
within the terminal phosphate. A solution to this problem was proposed by
introducing electrophilic phosphorylating reagents, such as cyanoethyl phosphate or
thiophosphate P-imidazolides, which are capable of reacting with non-activated
nucleotides (Fig. 7) [89]. Such reagents were shown to react with a series of
phosphates, phosphorothioates, and seleno- and borano-phosphates, which was
followed by one-step removal of cyanoethyl-protecting groups, provided straight-
forward access to a-modified nucleoside diphosphates and b-modified
triphosphates.
The P-imidazolide-based approach was employed for the synthesis of many
phosphate-modified cap analogs used as research tools for probing interaction with
cap-binding proteins and enzymes. One example is a therapeutically important cap
analog called b-S-ARCA [80, 90], bearing a 20-O-methyl group within the ribose of
7-methylguanosine and a phosphorothioate modification at the b position of the
triphosphate bridge (Fig. 8a). The synthetic pathway included two consecutive
ZnCl2-mediated coupling reactions: first P-imidazolide of 2
0-O-methyl-7-methyl-
guanosine monophosphate was reacted with triethylammonium thiophosphate and
the resulting b-thiodiphosphate was coupled with P-imidazolide of guanosine
monophosphate. Notably, the final product was obtained as a roughly equimolar
mixture of RP and SP diastereoisomers resulting from the b-phosphate modification.
Nonetheless, diastereoisomeric cap analogs could be separated by semi-preparative
reversed-phase (RP) HPLC even at a multi-milligram scale.
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Another example of the usefulness of MCl2-mediated coupling reactions
involving P-imidazolides is the synthesis of a symmetrical two-headed tetraphos-
phate cap analog [91], which was found to be a potent inhibitor of Dcp2 decapping
enzyme acting as an mRNA 50 cap mimic [27, 66]. Owing to the symmetry of the
final compound, it was possible to perform two coupling reactions in one synthetic
step, starting with P1,P2-diimidazolyl-pyrophosphate and two equivalents of
7-methylguanosine 50-phosphorothioate (Fig. 8b).
MCl2-mediated coupling reactions usually reach very high conversion of
reactants in a reasonable length of time (1–48 h depending on the sterical
hindrance); however, they require an excess of divalent metal chloride (4–16 molar
equivalents) [77, 78]. ZnCl2, MgCl2, or MnCl2 are the most commonly used for that
purpose (Fig. 8). The role of metal ions is probably complex and has never been
studied in detail, but the catalytic effect could be mainly attributed to three aspects
related to the formation of phosphate complexes (Fig. 8d): (i) eliminating the
electrostatic repulsion between negatively charged moieties and templating the
reactants, (ii) increasing the solubility of reactants in an organic solvent (usually
DMF), and (iii) increasing the electrophilicity of phosphorus atoms by complexation
of imidazole.
Fig. 7 Reactivity scope and limitations of P-imidazolides as substrates for the synthesis of chemically
modified phosphate derivatives
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2.5.3 Phosphate-Modified Cap Analogs as Molecular Probes for Cap-Dependent
Processes
A significant number of dinucleotide phosphate-modified cap analogs carrying
single or multiple O-to-X substitutions in the tri- or tetraphosphate chain (where X
is a single atom or a group of atoms) have been systematically studied over the last
decade to probe the structural requirements of eIF4E protein for cap recognition
[81, 83, 86, 92, 93]. These studies revealed that while some modifications disturb
recognition by eIF4E, some have a rather negligible effect, whereas others stabilize
the cap-eIF4E complex (Fig. 9). The affinity of eIF4E influences the ability of the
cap to promote mRNA translation, thereby modulating properties of mRNA
molecules in vitro and in vivo, as described further in chapter 2.4.4. Similarly,
phosphate-modified m3G cap analogs were employed to study interaction of m3G
cap with SNP1, degradation by hNudT16, and nuclear import of m3G cap
bioconjugates [94–96].
Phosphate moieties of small molecule cap analogs such as 7-methylguanine
mononucleotides or dinucleotides can be easily modified to carry a spectroscopic
label sensitive to changes in the local environment caused by protein binding or
enzymatic cleavage. Synthesis of such probes can be achieved by chemical
modification of the terminal phosphate moiety in a mononucleotide. The terminal
phosphate can be conveniently functionalized using a variety of chemistries to
Fig. 8 Synthetic pathways leading to important chemically modified cap analogs. a The key steps in the
synthesis of b-S-ARCA analog; b synthesis of a two-headed tetraphosphate cap analog—inhibitor of
Dcp2 enzyme; c synthesis of a cap analog containing a c–d imidodiphosphate moiety in the
tetraphosphate bridge; d putative role of divalent metal cations in coupling reactions. Reagents:
(i) imidazole, 2,20-dithiodipyridine (DTDP), triphenylphosphine (Ph3P), triethylamine (TEA), DMF; (ii)
triethylammonium thiophosphate, zinc chloride, DMF; (iii) thiophosphoryl chloride, 2,6-
dimethylpyridine, trimethyl phosphate; (iv) zinc chloride, DMF
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enable label attachment. These include nucleophilic substitution reaction of
nucleotide imidazolides with a phosphate nucleophile carrying the label described
above, S-alkylation of the thio-analogs with alkylhalide derivative of the label, and
copper-catalyzed azide-alkyne cycloaddition of an alkyne functionalized cap analog
with an azido compound (Fig. 2). The P-imidazolide approach has been used for the
synthesis of fluorophosphate analogs of 7-methylguanosine mononucleotides:
m7GMPF, m7GDPF, and m7GTPF (Fig. 2a) [84]. The compounds were tested as
19F NMR probes for cap-related processes. m7GTPF was used as a binding probe for
eIF4E in a 19F NMR assay based on changes in the transverse relaxation rate upon
binding by the protein [84]. All three compounds: m7GMPF, m7GDPF, and
m7GTPF, were found useful for monitoring activity of DcpS as they were cleaved
by the enzyme to m7GMP and a corresponding fluorine-containing leaving group: a
fluoride anion, fluoromonophosphate, and fluorodiphosphate, respectively. Each of
the products could be detected due to different dF chemical shifts compared to the
corresponding substrate (Fig. 10a) [84]. As a more sensitive alternative to 19F NMR
experiments, a fluorescent inhibitor screening assay for DcpS based on P–F bond
cleavage in m7GMPF and the use of a fluoride-sensitive chemosensor for product
quantitation has been developed (Fig. 10b) [97].
S-alkylation of ATPcS and GTPcS has been used for preparation of fluorescent
activity and binding probes for ATP and GTP binding proteins, with GTPcSBO-
DIPY as the best known example [98]. Recently, S-alkylation of a thio analog of
m7GTP, namely m7GTPcS, has been used to synthesize an acetylpyrene-(AcPy)-
labeled probe, m7GTPcSAcPy (Fig. 2b) [99]. Comparison of the fluorescent
properties of m7GTPcSAcPy with AcPy-thiophosphate and GTPcSAcPy revealed
that the cationic form of m7G enhances AcPy fluorescence up to threefold, in
contrast to guanine which is a strong AcPy quencher. As a consequence, the
fluorescence intensity of m7GTPcSAcPy decreased upon cleavage by DcpS, which
Fig. 9 Influence of cap triphosphate chain modifications on affinity to translation initiation factor 4E and
susceptibility to decapping enzymes (listed are modifications conferring resistance/decreasing
susceptibility to either enzyme)
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enabled both online DcpS activity monitoring as well as inhibitor screening assay
development (Fig. 11c) [99]. The vivid difference between the influence of guanine
and 7-methylguanine on AcPy fluorescence opens avenues for using GTPcSAcPy to
study biologically relevant guanine N7 methylation processes.
2.5.4 mRNA Modification with Synthetic Cap Analogs (Transcription In Vitro)
Beside their use as small molecular ligands, phosphate-modified dinucleotide cap
analogs can be used as reagents for mRNA 50 end modification, as previously
reviewed by us in detail [92].
The incorporation of dinucleotide cap analogs into RNA can be achieved co-
transcriptionally by in vitro transcription reactions. To this end, a DNA template
encoding G as the first transcribed nucleotide is transcribed by a bacteriophage RNA
polymerase in the presence of all four NTPs, and a dinucleotide m7GpppG. The
transcription is initiated by the nucleophilic attack of the 30-OH group of guanosine
from m7GpppG or GTP on the a phosphate of the second transcribed nucleotide to
produce, eventually, a mixture of capped and uncapped transcripts (Fig. 12). To
increase the fraction of capped RNAs in the transcription product (capping
efficiency), the concentration of GTP in the reaction mixture is usually decreased,
whereas m7GpppG concentration is elevated (up to tenfold over GTP) [100].
Pasquinelli et al. have shown that T7 RNA polymerase can initiate the transcription
by the attack of the 30-OH group of 7-methylguanosine in m7GpppG, thereby
incorporating the dinucleotide in the so-called reverse orientation (Fig. 12) [46].
Such event results in 30–50% of capped mRNAs having non-functional cap
structures, which are not translated efficiently by cap-dependent mechanisms. A
solution to that problem was proposed in the form of anti-reverse cap analogs
(ARCAs). These analogs are modified (or blocked) at the 30- or 20-OH hydroxyl of
7-methylguanosine to prevent recognition of this moiety by RNA polymerase
Fig. 10 Various approaches to cap analog functionalization via terminal phosphate. a Synthesis of
7-methylguanine mononucleotides labeled with fluorine atom via phosphorimidazolide chemistry;
b synthesis of cap analogs carrying an acetylpyrene label via S-alkylation of the terminal
phosphorothioate group; c synthesis of triazole-containing dinucleotide analogs via CuAAC
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[36, 101, 102]. The simplest and most commonly used modification is methylation
of one of those groups, but ARCAs containing hydrogen (O–H substitution) or
fluorine (O–F substitution) or even bulkier substituents have also been reported
[37, 38, 103–106]. Importantly, chemical modifications at these positions do not
affect interactions with eIF4E or translation efficiency of such capped mRNAs,
although, in the case of some bulkier substituents, the translation efficiency can be
slightly decreased in comparison to ARCAs carrying simply a methyl group
[37, 38]. Adenine dinucleotides such as NAD, FAD, and dpCoA can be introduced
into RNA 50 ends by transcription in vitro of a DNA template encoding A as the first
transcribed nucleotide [107].
Importantly, the co-transcriptional capping approach opens the possibility for
straightforward introduction of chemical modifications into the cap. First, the ‘anti-
reverse’ type modifications of the m7G cap can be additionally functionalized to
carry a label or a biological tag such as biotin or fluorescent dye. Second, a number
of phosphate-modified nucleotides were shown to be accepted as transcription
initiators for T7 and SP6 RNA polymerases, giving access to phosphate-modified
capped mRNAs as tools to study the specificity of cleavage by RNA-dependent
capping enzymes, with Dcp1/2 being the prime example [64, 65, 108]. Two
methylene-bisphosphonate ARCAs differing in the site of O to CH2 substitution
(either a–b or b–c, Fig. 9) allowed for differential inhibition of decapping pathways
[64]. First, in vitro experiments were performed on short radiolabeled RNAs to
Fig. 11 Applications of phosphate-modified cap analogs for monitoring or assaying activity of the
human DcpS enzyme. a DcpS activity monitoring using 19F NMR and m7GTPF as a substrate; b the idea
of high-throughput inhibitor screening assay for DcpS using m7GMPF as a substrate and a fluoride-
sensitive chemosensor as a fluorogenic probe; c assaying DcpS activity by monitoring hydrolysis of an
acetylpyrene-labeled fluorescent probe
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determine the susceptibility of the modified caps to recombinant hDcp2. It was
found that the RNAs with the cap modified at the a–b position were resistant to
cleavage by Dcp2, while the RNAs with the cap modified at the b–c position were
similarly susceptible to the unmodified cap. A study on degradation of full-length
mRNAs in mammalian cells revealed that preventing the cleavage at the a–b
position of the triphosphate bridge (performed by Dcp1/2) increases the half-life of
mRNA. This observation combined with earlier studies which showed that
modification at the b-c position protects the cap from cleavage only by DcpS
leads to the conclusion that cap degradation is a limiting step for the 50–30
degradation pathway but not for the 30–50 pathway (Fig. 9).
Fig. 12 Synthesis of capped RNAs by so-called co-transcriptional capping during transcription in vitro.
a General scheme of the process; b structural requirements for a cap analog to be incorporated into
mRNA and to produce anti-reverse cap analogs (ARCAs)
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Despite the extended half-life of mRNAs capped with a-b modified analogs, such
transcripts had poor translational properties, which inspired the quest for novel cap
structures that could confer to mRNA both resistance to Dcp2 and high translational
efficiency. The first analogs, which combined these two features, were compounds
carrying a non-bridging O–S substitution at the beta position of the triphosphate
chain, referred to as b-S-ARCAs [108]. Later, it was found that similar properties
could be conferred to mRNA by an O-to-BH3 substitution [65, 83]. Recent studies
have shown that applying two O–S substitutions at two adjacent phosphate moieties
in a tri- or tetraphosphate bridge may provide biological properties superior to b-S-
ARCA [81]. A series of phosphate-modified analogs carrying O-to-S, O-to-NH,
O-to-BH3, and O-to-Se substitutions at different positions have been used to study
mRNA degradation in HeLa cells [65].
Typically, even small bridging modifications of the oligophosphate chain
decrease the translation potential of mRNA, but the relation between size of the
substituent and biological properties is not so obvious. Recently, a series of 34 cap
analogs carrying a 1,2,3-triazole moiety within the oligophosphate chain were
synthesized using copper-catalyzed azide-alkyne cycloaddition [86]. Biochemical
evaluation of RNA co-transcriptionally capped with these analogs led to identifi-
cation of two analogs, which despite this bulky triazole modification had
translational properties similar to cap structures carrying an unmodified triphosphate
chain. This unexpected finding highlights possibilities of novel approaches towards
the synthesis of small molecule cap analogs as well as capped RNAs.
2.5.5 Phosphate Modifications for Chemical Capping Approaches
Over the 40 years since the discovery of the cap structure, chemical synthesis has
provided access to a still-growing library of small molecule cap analogs, while the
molecular biology techniques enabled incorporation of these structures into long
RNAs. Somewhat surprisingly, exploring the ‘middle ground’—which is the
efficient synthesis of short capped oligonucleotides in high purity—still poses a
challenge both for chemistry and biology. Short m7GpppRNAs, m3GpppRNAs, and
NAD-RNAs have been synthesized by chemical reaction of RNA-50 phosphates
with appropriate imidazole-activated nucleotides under aqueous conditions
[109–112], but these reactions are only moderately efficient and require time-
consuming chromatographic and/or enzymatic work-ups to separate capped and
uncapped RNAs. An improvement in solution synthesis of capped oligomers has
been proposed by using a 4,40-dimethoxytrityl (DMT) group as a lipophilic
purification handle, which facilitates separation of capped RNAs from uncapped
RNAs by RP HPLC [113]. Solid-phase synthesis of capped oligonucleotides has
been attempted as well, but found to be challenging due to incompatibility of the
m7G moiety with standard oligonucleotide de-immobilization and de-protection
protocols [114–118]. Combination of RNA capping via these approaches with
phosphate modifications appears even more challenging and remains to be
demonstrated.
As such, a universal non-enzymatic method for the generation of bulk amounts of
short capped RNAs would be of great interest to both chemical and biological
Top Curr Chem (Z) (2017) 375:16 Page 21 of 29 16
123
communities. To this end, alternative approaches to chemical RNA capping based
on click chemistry have recently come into focus. One interesting alternative to the
P-imidazolide approaches that has been recently proposed is based on the selective
reaction of benzyl diazomethane derivatives with the terminal phosphate of
unmodified RNA 50-(mono/di/tri)phosphates to give appropriate benzyl esters [119].
Such a reaction was applied for the functionalization of the RNA 50 end with an
orthosteric inhibitor of translation targeting the cap-binding site of eIF4E (Fig. 13a).
Another example is chemical functionalization of short RNAs containing a modified
50-(oligo)phosphate carrying an alkyne handle with azide-containing m3G cap
analogs or 50-azido-50-deoxy-7-methylguanosine (Fig. 13 b, c) [86, 96]. Interest-
ingly, some RNAs capped with m3G analogs obtained by CuAAC were still found
to be recognized by decapping enzyme hNudT16, suggesting that these types of
conjugates may be useful for biochemical and structural studies [96]. Conditions for
high-yielding RNA click modifications that enables retaining desired biological
activities of capped RNAs is yet to be determined, but if achieved it could finally
provide access to high-yielding synthesis of short capped RNA mimics.
3 Summary and Future Prospects
Cap is a natural tag attached to the 50 end of messenger RNA and small nuclear
RNA, which due to its unique structural features fulfills essential biological
functions during the process of gene expression. The ‘inverted’ 50-to-50 triphosphate
bridge, alongside with a 7-methylguanosine moiety, is one of the two crucial
elements of the mRNA cap structure. The triphosphate bridge is a site of cleavage
for RNA decapping enzymes and is involved in the electrostatic interactions with
other cap-related proteins. Therefore, synthetic cap analogs modified within the
triphosphate bridge or carrying spectroscopic labels attached to phosphate moieties
turned out to be valuable tools for studies on mRNA metabolism, modification of
natural mRNA properties, or molecular probes for screening inhibitors of cap-
dependent processes/proteins. Biorthogonal methods for modification of biologi-
cally relevant molecules give exceptional opportunities to follow or even to
manipulate these processes inside the cells. mRNA has a great potential for use as a
therapeutic agent in gene therapy, emerging in several ongoing clinical trials, which
is a driving motivation for the development of new molecular tools for mRNA cap
modification and for the construction of new cap-based molecular probes. Much
progress has been made in microscopic techniques and single-molecule experiments
allowing investigation into the properties of individual molecules, and providing
another motivation to develop new methods for mRNA cap-labeling. The authors of
this chapter are convinced that the coming years will bring intensification of studies
aimed at developing new applications of labeled cap analogs in a cellular context.
The continuous improvements in understanding of how the cap interacts with its
cellular partners, protein factors, and decapping enzymes lead us to believe that in
the future, modifications introduced into the mRNA cap structure will minimize the
interruption of mRNA biological functions. Progress in the design and synthesis of
molecular probes will enable investigation of processes that are poorly understood,
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such as cellular correlation between initiation of translation and mRNA degradation,
post-transcriptional methylation of mRNA 50 end, and antiviral immune response.
The discovery of structures similar to the mRNA cap, such as the NAD cap in
bacteria, may also open a new chapter in this field. Various approaches applied for
the investigation of mRNA and snRNA caps can be adapted to study biological
functions of their bacterial relatives. Finally, advancements in screening method-
ologies will allow researchers to find more selective inhibitors of cap-dependent
processes with high therapeutic potency. The immense progress in nucleotide and
nucleic acid delivery methodologies we are currently witnessing will likely bring
phosphate-modified cap analogs to in vivo applications.
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Fig. 13 Modification of the RNA 50 end by direct attachment of cap analogs or mimics (chemical
capping). a Chemical esterification of phosphorylated RNA using a diazobenzyl derivative of translation
inhibitor-targeting eIF4E protein; b application of CuAAC for conjugation of a dinucleotide m3G cap
analog and chemically synthesized RNA; c chemical capping of enzymatically synthesized RNA with 50-
azido-50-deoxy-7-methylguanosine under CuAAC conditions
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